Montrealer Janice Murray named President of Novartis in Canada

• Chief Financial Officer for Novartis Pharmaceuticals Latin America and Canada Region takes over leadership of one of Canada's leading pharmaceutical companies

DORVAL, QC, May 3, 2017 /CNW/ - Montrealer Janice Murray, a long-time employee of Novartis Pharmaceuticals Canada Inc., has been named President, effective May 1, 2017.

Along with its Dorval-based Pharmaceuticals and Oncology business, other Novartis operations in Canada are Alcon Canada, specializing in eye care products and headquartered in Mississauga, Ontario, and Sandoz Canada, providing generic drugs, biosimilars and over-the-counter treatments, based in Boucherville, Quebec.

Janice moves to her new position after having been in the role of Chief Financial Officer for the Latin America and Canada Region of Novartis Pharmaceuticals, a position she held while based in Dorval. In this position, she oversaw the strategic planning, budgeting, financial performance, compliance and supply chain management of the region's six operating units with combined revenues of approximately $2 billion.

Prior to this regional role, Janice was Vice President of the Ophthalmology Business Franchise for Novartis Pharmaceuticals Canada for four years, leading the team of sales and marketing associates responsible for the company's largest business franchise. She joined Novartis Pharmaceuticals Canada as Chief Financial Officer in 2006.

Janice holds a Bachelor of Commerce degree in accounting from the University of Ottawa, a Graduate Diploma in Accountancy from McGill University in Montreal, and a Chartered Accountant designation from the Ordre des comptables agréés du Québec. She started her career in audit management with KPMG Chartered Accountants and then spent 13 years in various senior and executive positions at Canadian National Railway before joining Novartis.

About Novartis in Canada
Novartis has 1,800 associates across Canada providing innovative healthcare solutions to Canadians through its three divisions: Innovative Medicines (pharmaceutical and oncology), Alcon Canada (eye care) and Sandoz Canada (generic medicines, biosimilars and over-the-counter treatments). Novartis invested $49 million in research and development in Canada in 2016. For further information, please consult www.novartis.ca, www.alcon.ca, and www.sandoz.ca.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2016, the Group achieved net sales of USD 48.5 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit http://www.novartis.com.

SOURCE Novartis Pharmaceuticals Canada Inc.

Novartis Media Relations: Katrina Lucking, Novartis Corporate Communications, [phone], E-mail: [email protected]; Spectrum Advisors, [phone], [email protected]